Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
epilepsy
Biotech
Axsome adds AZ asset through Avenue subsidiary acquisition
Axsome is after BAER-101, a phase 2 oral GABA receptor modulator that Avenue's Baergic Bio originally licensed from AstraZeneca in December 2019.
Darren Incorvaia
Nov 6, 2025 10:50am
Angelini signs $550M-plus neuro pact with South Korean biotech
Sep 22, 2025 1:47pm
Rapport's seizure drug hits in phase 2, sending stock soaring
Sep 8, 2025 8:25am
Jazz pays Saniona $42.5M to add prospect to epilepsy ensemble
Aug 20, 2025 9:13am
J&J calls time on Addex partnership a year after epilepsy fail
Apr 17, 2025 7:05am
Atalanta’s RNA epilepsy asset suppresses seizures in mice
Apr 10, 2025 5:30am
